Patients with postherpetic neuralgia may experience various sensory signs and symptoms of pain. Despite this, the recommendations for medicinal treatment do not differ accordingly. In order to find the appropriate treatment options for postherpetic neuralgia, several attempts have been made in the past. The crucial obstacle to these attempts was insufficient or no subgrouping of patients according to their sensory phenotype, mostly resulting in an unsatisfactory treatment response. Recently, a new concept of retrospective stratification according to the patients' sensory phenotype has been made in a large cohort of pain patients. This new stratification tool allows a predictive validity for treatment response in subgroups of patients and might be of potential value in determining the optimal treatment in postherpetic neuralgia patients.
Scrutiny of the existing evidence base for pharmacologically based analgesic therapies in established postherpetic neuralgia (PHN; defined as persistent pain for ≥3 months after the resolution of cutaneous lesions) reveals that currently available therapies are generally of modest efficacy and have a narrow therapeutic index [1] . Furthermore, the benefit of an individual treatment is generally only achieved in a minority of those patients who are treated. The foregoing statements are based on a recent systematic review and meta-analysis of randomized controlled trials (RCTs) for neuropathic pain and Grading of Recommendations Assessment, Development, and Evaluation (GRADE)-based treatment guidelines, based on that evidence [2] . For the purposes of this article we have extracted the data from the original systematic review of RCTs that specifically reported data for PHN patients and also updated our search up to March 2017. This includes data from a total of 44 placebo-controlled RCTs. The numbers needed to treat (NNT) for 50% pain reduction, with interventions that are recommended for neuropathic pain, and where there is some evidence of benefit, are summarized in Figure 1 .
For orally administered tricyclic antidepressants we included in the meta-analysis 3 RCTs that randomized a total of 126 subjects ( Figure 1A) . One RCT compared a median dose of amitriptyline 75 mg to placebo [3] . The second compared placebo to desipramine (mean daily dose 167 mg/day) [4] . In the third RCT nortriptyline (mean daily dose 89 mg/day) or desipramine (63 mg/day) were compared to placebo and an opioid [5] . Overall, the number needed to treat to obtain 50% pain relief (NNT 50% [95% confidence interval]) was 2.53 (2.0-3.5), which compares to 4.29 (3.5-5.4) for tricyclic antidepressants in neuropathic pain of all causes [2] . The combined number needed to harm (NNH) for 1 patient to drop out of the study because of side effects was 14.63 (6.9-123) . Two further RCTs support the use of amitriptyline for PHN but we were unable to extract metadata from these [26, 27] . We were unable to locate any suitable RCTs that reported PHN-specific data for duloxetine or other serotonin-noradrenaline reuptake inhibitors.
For orally administered gabapentin we identified 6 placebo-controlled RCTs that met our inclusion criteria and which randomized a total of 1956 patients (see Figure 1B ). The first trial titrated patients to a maximum dose of 3600 mg/day [6] and the second RCT was of a similar design but force titrated to doses of 1800 or 2400 mg/day of gabapentin [7] . Three RCTs reported data for a gabapentin extended-release formulation with NNTs ranging from 6.5 to 12.8. The first of these RCTs examined a total daily dose of 1800 mg/day in 1 of 2 dosing regimens and reported superiority to placebo [8] . Conversely, the second RCTs with different dosing regimens of 1800 mg/day were compared to placebo, but the primary efficacy endpoint was not met [9] . The third RCT also examined gabapentin 1800 mg/day [10] . A final RCT compared 3 doses of gabapentin enacarbil 1200-3600 mg to placebo and reported efficacy [11] . The overall NNT 50% for gabapentin in PHN, including modified release and gabapentin enacarbil, was 6.51 (5.2-8.8) , which compared to 7.2 (5.9-9.2) for neuropathic pain in general [2] . The combined NNH was 12.93 (13.8-53.0) . A final RCT compared gabapentin enacarbil 1200-3600 mg/day to placebo [11] .
For orally administered pregabalin, we identified 5 published RCTs that met our inclusion criteria, in which a total of 1386 patients were randomized [12] [13] [14] [15] [16] , and 1 unpublished trial (ClinTrials.gov NCT00394901) ( Figure 1C ). All RCTs examined doses of between 300 and 600 mg/day. The overall NNT 50% for pregabalin in PHN was 4.71 (3.9-6.0), which compared to 7.8 (6.7-9.4) for neuropathic pain in general [2] . The combined NNH was 8.15 (6.3-11.5) .
We identified a single RCT that compared orally administered tramadol (mean daily dose 275 mg/day) to placebo in 127 randomized patients [17] (Figure 1D ). The NNT 50% was 4.76 (2.8-27) , compared with 5.07 (3.8-7.7) for neuropathic pain in general. The NNH was 10.67 (6.1-44.8).
For more potent orally administered opioids, 3 RCTs met our inclusion criteria and these randomized a total of 136 patients ( Figure 1E ). Oxycodone to a mean daily dose of 45 mg/day [18] , morphine at mean daily dose of 91 mg/day or methadone 15 mg/day [19] and methadone 10 mg/day [20] were all examined. The overall NNT 50% for potent opioids in PHN was 2.77 (2.1-4.1), which compared to 4.31 (3.4-5.9) for neuropathic pain in general [2] . The overall NNH was 11.3 (5.9-147).
There is 1 phase 2 RCT reporting evidence of efficacy in PHN for EMA401, an angiotensin 2 receptor antagonist, which is in preregistration development [28] .
In terms of topically administered treatments, we identified 2 RCTs that examined capsaicin 0.075% cream, in which 175 patients were randomized [29, 30] . Combined, these yielded an NNT 50% of 3.04 (2.14-5.27) compared to 7.05 (4.6-14.8) for neuropathic pain in general [2] . The combined NNH was 5.67 (3.8-11.4) . We were unable to extract metadata from a small RCT examining liposomal capsaicin 0.025% in 14 randomized patients, which was reported as negative [31] . For topical capsaicin 8% plaster, 1274 patients were randomized in 4 RCTs 
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There is emerging evidence to support the use of botulinum toxin A injection [2, 33] . We were able to extract data from a single RCT of botulinum toxin A, which randomized 30 patients [25] and yielded NNT 50% 1.15 (0.96-1.4) compared to 2.44 (1.9-3.4) for neuropathic pain in general [2] (Figure 1G ).
For nonpharmacological therapies there is scant evidence of efficacy in PHN or indeed in neuropathic pain in general. A recent Cochrane review reported insufficient evidence for the efficacy and safety of psychological interventions in chronic neuropathic pain [34] . This is despite a study suggesting that PHN may be a suitable condition for the development of psychological-based therapies [35] . There is a similar lack of evidence for invasive therapies including neuromodulation [36] , a particular problem here being the lack of RCTs employing the essential precaution of placebo control when assessing the effectiveness of surgical and invasive procedures where pain relief is an outcome [37] .
It should be emphasized that the foregoing discussion is based on reports of RCTs where only group-level data are generally reported, and there are few available data regarding the responses at the individual patients and the phenotypic characteristics of those patients.
TOWARDS A MECHANISMS-BASED TREATMENT
Various authors have proposed that a classification of neuropathic pain should be based on the underlying mechanism of pain generation (mechanism-based classification of neuropathic pain) rather than on the etiology of the disease [38, 39] . This classification scheme would pave the way for an individualized pharmacological treatment of postherpetic neuralgia not only by identifying new therapeutic targets but also in describing which patients are likely to respond to a specific treatment. Because it is difficult to unravel mechanisms of pain in human patients one has to rely on surrogate markers of mechanisms. One promising approach claims that the expression of sensory signs and symptoms as elicited by the examiner, the so-called "sensory profile" of a patient, might be a reflection of the underlying mechanisms. This concept has led to the development of a symptom-oriented diagnostic approach to neuropathic pain and postherpetic neuralgia, which supplements the etiology-based classification scheme. A symptom-oriented approach does not negate the fact that distinct neuropathies have different clinical presentation, and that some neuropathic disease states may predispose to certain constellations of pain symptoms (eg, touch-evoked pain in postherpetic neuralgia). Therefore, this approach's aim is not to implement a new subclassification specifically for PHN. By stratifying patients according to their sensory profile the practitioner should be guided to a certain pharmacological treatment that targets the underlying neuropathic pain mechanism, regardless of the pain entity. In the future, treatment studies using mechanism-based classification, prospectively stratifying patients according to their sensory symptoms and signs, are needed [40] .
SUBGROUPING OF PATIENTS BASED ON SENSORY SIGNS
Almost 20 years ago, a first attempt was made to subgroup patients with postherpetic neuralgia based on the thermal sensitivity of the skin, the cutaneous reaction to histamine, the results of skin biopsies, and the presence or absence of allodynia. Two main subtypes of patients were proposed: patients with irritable nociceptors (nociceptor defined as: "a high-threshold sensory receptor of the peripheral somatosensory nervous system that is capable of transducing and encoding noxious stimuli" [41] ) and patients with deafferentation (deafferentation defined as: a destruction or interruption of peripheral afferent nerve fibers) [42] . In 2006, a standardized quantitative sensory testing (QST) protocol for clinical trials was introduced by the German Research Network on Neuropathic Pain [43] to assess a whole spectrum of abnormal sensory perceptions in neuropathic pain patients. The test battery consists of 7 tests, including different thermal and mechanical stimuli that examine perception, as well as pain thresholds. The assessment of thermal thresholds is conducted by a thermotest device (TSA 2001-II, Medoc, Ramat Yishai, Israel or MSA, SOMEDIC, Hörby, Sweden), with a thermoprobe placed at the skin. The mechanical stimuli are performed with standardized test hairs of different diameters (von Frey hairs, Fruhstorf), the application of altering pinprick (metal pin) forces, a brush, cotton wool, a cotton swab, and a pressure algometer (FDN200; Wagner Instruments, Greenwich, CT). The dynamic mechanical allodynia is quantified by applying 50 painful and nonpainful stimuli (via brush, cotton wool, cotton swap, pinpricks) to the skin and instructing the patient to rate these perceptions on a numeric scale reaching from 0 (no pain) to 100 (worse pain). The evaluation of deep somatic allodynia is conducted by instructing the patient to indicate when the pressure applied with the pressure algometer turns into a painful stimulus. This QST protocol allows the determination of small (C-and Aδ-fiber) and large (Aβ-fiber) afferent fiber functions, as well as positive and negative sensory signs. Based on these sensory QST profiles, a statistical segmentation of patients has been performed using a hierarchical cluster analysis. This approach identifies patterns or dimensions of sensory signs that occur most frequently without using a priori hypothesis or other predefined assumptions. Using QST data from more than 1100 patients with peripheral neuropathic pain, 3 distinct subgroups with characteristic sensory profiles were identified (Figure 2) .
The first subgroup was characterized by preserved sensory functions in combination with thermal hyperalgesia and mild mechanical allodynia. Subgroup 2 showed a loss of small and large fiber function. Subgroup 3 demonstrated a loss of small fiber function in combination with pinprick hyperalgesia, marked dynamic mechanical allodynia, and deep somatic allodynia. About 27% of the PHN patients fall into group 1, 25% into group 2, and 48% into group 3 [44] .
Other possibilities to assess symptoms in neuropathic pain patients are patient-reported outcomes (questionnaires such as the PainDETECT Questionnaire [45] and the Neuropathic Pain Symptom Inventory [46] ). Pain symptoms are evaluated directly by the patients and therefore can be used to phenotype patients on the basis of their perceived sensory abnormalities.
With this approach we found 5 distinct subgroups of sensory symptoms assessed with painDETECT in 498 patients with postherpetic neuralgia. In contrast to the QST, which evaluates stimulus-evoked sensations, questionnaires mainly assess spontaneous pain-related sensations such as burning pain or prickling [47] .
TREATMENT STUDIES USING MECHANISM-BASED CLASSIFICATION
The next important step in establishing an individualized, mechanism-based therapy is to prove that patients classified into different mechanistic groups respond differently to pharmacological pain treatments.
Retrospective analyses of signs and symptoms of neuropathic pain patients at baseline have, in several studies, demonstrated that patients with distinct profiles respond differently to a certain therapy.
In 2004, Attal et al found, in 22 patients with pain due to traumatic nerve injury or postherpetic neuralgia, that dynamic or static mechanical allodynia assessed by QST appeared to be predictive of the response to intravenously administered lidocaine [48] . In another study by Attal et al, examining the effect of intradermally injected botulinum toxin A in patients with postherpetic neuralgia or posttraumatic/postoperative neuropathy, showed a correlation between the analgesic effect and preserved thermal sensibility at baseline, indicating intact cutaneous innervations [33] . In 2005, Wasner et al, examining the association between the treatment response to topical lidocaine and the function of thermosensitive and histamine-sensitive cutaneous afferents in PHN patients, showed a significant pain reduction in patients with impaired nociceptor function [49] .
Post hoc stratification according to the sensory profile or sensory phenotype showed promising results for subgroups of patients. In order to get one step closer towards an individualized pharmacological treatment of neuropathic pain, studies prospectively stratifying patients according to their sensory symptoms and signs are needed [50] .
Recently, Demant et al examined in a randomized, double-blinded, placebo-controlled trial the pain-relieving effect of oxcarbazepine in 72 patients with postherpetic neuralgia, surgical or traumatic nerve injury, or polyneuropathy [51] . They performed QST at the beginning of the trial and stratified patients according to their sensory profile into the 2 groups: (1) "irritable nociceptor" with predominantly a "gain of function" Sensory profiles of patients with peripheral neuropathic pain. Three subgroups identified by k-means clustering presented as mean ± SEM (n = 902). Positive z scores indicate positive sensory signs (hyperalgesia), negative z values indicate negative sensory signs (hypoesthesia, hypoalgesia). Dotted lines: 95% confidence interval for healthy subjects (−1.96 < z < +1.96). Black symbols, cluster 1 "sensory loss" (42%); grey symbols, cluster 2 "thermal gain" (33%); white symbols, cluster 3 "thermal loss/ mechanical gain" (24%). Dynamic mechanical allodynia (DMA) was most pronounced in cluster 3, which also exhibits the most pronounced hyperalgesia to pinprick (MPT, MPS) and blunt pressure (PPT). Paradoxical heat sensations were most pronounced in cluster 2, associated with diminished cold detection (CDT) but not cold hyperalgesia (CPT) [44] . Abbreviations: CDT, Cold detection threshold; CPT, cold pain threshold; DMA, dynamic mechanical allodynia; HPT, heat pain threshold; MDT, mechanical detection threshold; MPS, mechanical pain sensitivity; MPT, mechanical pain threshold; NRS, numeric rating scale; PHS, paradoxical heat sensations; PPT, pressure pain threshold; QST, quantitative sensory testing; TSL, thermal sensory limen; VDT, vibration detection threshold; WDT, warm detection threshold; WUR, wind-up ratio.
and preserved small-fiber nerve function; and (2) "deafferentation type" dominated by sensory loss. This stratification is based on the assumption that ectopic activity from upregulated sodium channels is mainly responsible for hyperalgesia ("irritable nociceptor") and therefore oxcarbazepine as a sodium channel blocker should have an effect on these patients. Although oxcarbazepine is recommended as first-line therapy for trigeminal neuralgia, it plays a minor role for the treatment of other neuropathic pain syndromes, mainly due to controversial study results [52] . This study showed positive results and a treatment response depending on the sensory phenotype. For all patients the NNT 50% was 6.9; the NNT 50% in the group with the "irritable nociceptor phenotype" was only 3.9, whereas for the "nonirritable nociceptor" phenotype the NNT 50% was 13 [51] .
LIMITATIONS OF THE APPROACH
Attractive as subtype classification based on sensory profiles might be, it should be emphasized that not all PHN patients fit exactly into one category or the other. Furthermore, in a large group of PHN patients many heterogeneous patterns of sensory dysfunction were detected [40] . Accordingly, detailed testing of sensory function, chemical stimulation, and cutaneous innervation in one PHN patient clearly showed areas of relative preservation in close proximity to impaired thermal sensation, and both within the affected dermatome [53] . Moreover, the sensory patterns showed variation over the time course of PHN. However, by classification of PHN patients due to sensory abnormalities within the most painful skin area it is possible to detect the predominant individual sensory profile and most likely the underlying pain-generating mechanism.
FUTURE IMPLICATIONS FOR THERAPY AND CLINICAL TRIALS
The examples presented above highlight the importance of an individualized pain therapy to tailor appropriate treatment to the right patients. The challenge in implementing this individualized therapy concept is to identify appropriate subgroups of patients. At this point in time, the most promising approach to achieve this aim is to use the individual sensory profile as a surrogate for pain mechanisms. With QST and pain symptom questionnaires very promising results have already been revealed.
Given the problem of negative outcomes in many recent trials in PHN and other neuropathic pain syndromes, as well as the promising results of the symptom-based classification scheme so far, researchers and pharmaceutical companies are encouraged to implement this obvious and rational approach in future clinical trial designs.
CONCLUSIONS
Existing pharmacological therapies for PHN are of modest efficacy and only achieve satisfactory analgesia in a minority of patients. The pharmacological treatment of PHN should be conducted according to the 2015 Neuropathic Pain Special Interest Group (neuPSIG) guidelines for neuropathic pain, which are based on a systematic review and meta-analysis [2] . Beyond this, the treatment depends on the personal experience of the physician as well as on the patient's individual constitution and comorbidities. To date, these are the determining criteria to either prefer one compound or another. There are no high-quality data to support the use of either psychological or physical intervention (including neuromodulation) in PHN. Sensory profiling of patients with postherpetic neuralgia is a promising technique to group patients and to predict treatment response. As a result of the presented data, the European Medicines Agency (EMA) has recently acknowledged sensory profiling in a Committee for Medicinal Products for Human Use (CHMP) qualification advice. The sensory profiling and subgrouping as proposed in this study [44] is an adequate stratification tool for determining specific sensory phenotypes in exploratory trials on neuropathic pain [54] . This assessment should be implemented in future trial designs to ultimately prove or disprove the mechanism-based treatment concept.
At the moment, QST cost-efficiency is restrained because of high acquisition costs, the length of testing procedure (approximately 30 minutes per test side for a trained QST tester) and the special training course that has to be conducted in order to perform a standardized sensory test. Therefore, assessment tools (eg, a bed-side test) have to be developed that simply and reliably identify subgroups of patients in the general practitioner setting. Only if these prerequisites are fulfilled, could the method of targeting treatment to the appropriate patients be implemented in general practice. 
